Search
Cisplatin Treatment Options
A collection of 1422 research studies where Cisplatin is the interventional treatment. These studies are located in the United States. Cisplatin is used for conditions such as Head and Neck Cancer, Lung Cancer and Non-small Cell Lung Cancer.
409 - 420 of 1422
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Studying an Investigational Virus Vaccine
Recruiting
The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.
Conditions:
Healthy
Interested in vaccine studies
All Conditions
Preventative Trials
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Trial
Evaluating an Investigational Treatment for Hidradenitis Suppurativa
Recruiting
The main objectives of this Phase 2 study are to evaluate the safety and effectiveness of an investigational medication in adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition. Participants will be randomly assigned to receive the investigational treatment or a placebo. Should you express interest, the research site will contact you directly to provide further details and address any questions you may have about study requirements, risks/benefits, and compensation.
Conditions:
All Conditions
Hidradenitis suppurativa (Skin disorder)
Dermatology
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Completed
The purpose of this trial is to evaluate 2-year disease-free survival in this patient population treated with single agent cisplatin and patients treated with cisplatin in combination with Rucaparib following preoperative chemotherapy. Side effects and tolerability of this treatment in patients with residual disease following preoperative chemotherapy will also be observed and characterized.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/06/2024
Locations: St. Jude Heritage Healthcare, Fullerton, California +26 locations
Conditions: Breast Cancer
Evaluating Patients With Varying Degrees of Renal Function
Completed
This is a Phase I, open-label study evaluating the PK of S-1 components and their metabolites in patients with advanced solid tumors and varying degrees of renal function. Patients will be stratified by baseline 24-hour creatinine clearance(CrCL) into 4 cohorts using the normal clearance formula:
Group A: Control Group B:Mild renal dysfunction Group C:Moderate renal function and Group D: Severe renal dysfunction. Six patients will be enrolled into each cohort.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/30/2024
Locations: Premiere Oncology of Arizona, Scottsdale, Arizona +8 locations
Conditions: Renal Impairment
Evaluating Patients With Impaired Hepatic Function
Completed
This is a Phase I, Open-Label study evaluating the PK of S-1 components and their metabolites in patients with advanced solid tumors and varying degrees of hepatic function defined by the NCI classification for hepatic impairment. Patients will be stratified into 4 Cohorts- Normal, Mild, Moderate or Severe.
Six patients will be enrolled inot each cohort and receive S-1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/30/2024
Locations: Premiere Oncology of Arizona, Scottsdale, Arizona +5 locations
Conditions: Impaired Hepatic Function
Phase 1/2 Study of S-1 and Cisplatin in Advanced Gastric Cancer
Completed
The purpose of the phase 1 portion of the study is to determine the safe dose of S-1 and cisplatin that can be administered in gastric cancer patients.
The purpose of the phase 2 portion of the study is to determine the antitumor activity of the S-1 and cisplatin regimen established from phase 1 in patients with advanced gastric cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/30/2024
Locations: Rosen, Lee, Los Angeles, California +10 locations
Conditions: Gastric Cancer
A Safety and Efficacy Study in Patients With Gastric Cancer
Completed
This is an open-label, international, two-arm, parallel, randomized, Phase 3 study evaluating the efficacy and safety of S-1/cisplatin versus 5-FU/cisplatin in patients with advanced gastric cancer previously untreated with chemotherapy for advanced disease. Patients will be randomly assigned (1:1) to S-1/cisplatin (experimental arm) or 5-FU/cisplatin (control arm). Patients will be stratified by number of metastatic sites (one vs. more than one), locally advanced or metastatic disease, prior ad... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/30/2024
Locations: Clearview Cancer Center, Huntsville, Alabama +32 locations
Conditions: Gastric Cancer
Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial
Terminated
The purpose of this study is to evaluate the safety and efficacy of S-1 and Cisplatin compared to 5-FU and Cisplatin in treatment of patients with metastatic diffuse gastric and gastro-esophageal junction cancer previously untreated with chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/30/2024
Locations: Not set, Alexandria, Louisiana +86 locations
Conditions: Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction
Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors
Terminated
This study is planned to be conducted in 2 parts: Part 1: Dose Escalation and Part 2: Safety Run-In and Randomized Expansion.
The primary objectives of Part 1 are 1) To characterize the safety and tolerability of GS-3583 as monotherapy in participants with advanced solid tumors. 2) To determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of GS-3583 as monotherapy in participants with advanced solid tumors.
The primary objectives of Part 2 is to assess the safety and tol... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/28/2024
Locations: START Midwest, Grand Rapids, Michigan +3 locations
Conditions: Advanced Solid Tumors
Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)
Completed
The purpose of this study is to determine the efficacy and safety of pembrolizumab given concomitantly with chemoradiation (CRT) and as maintenance therapy versus placebo plus CRT in participants with locally advanced head and neck squamous cell carcinoma (LA HNSCC). The primary hypothesis is that pembrolizumab in combination with CRT is superior to placebo in combination with CRT with respect to event-free survival (EFS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/28/2024
Locations: UCLA Medical Center ( Site 0273), Los Angeles, California +150 locations
Conditions: Head and Neck Neoplasms
Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma
Active Not Recruiting
The purpose of this research study is to test the safety and the benefit of adding pembrolizumab (a therapy that activates the immune system to fight cancer) to standard of care treatment for head and neck cancer. The standard of care treatment will include surgery followed by radiation for 6 weeks. Some patients may also receive cisplatin as standard of care once a week for 6 weeks if the cancer is found to be "high risk". High risk includes cancer that was not completely removed (positive marg... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/27/2024
Locations: University of Louisville - James Graham Brown Cancer Center, Louisville, Kentucky +5 locations
Conditions: Head and Neck Cancer
S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer
Completed
The primary focus of this study is to see if looking at tumor biomarkers using a program called coexpression extrapolation or "COXEN" may predict a patient's response to chemotherapy before surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/26/2024
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +565 locations
Conditions: Bladder Cancer
Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma
Recruiting
Objectives: The investigators will test whether combination of chemoimmunotherapy or dual agent immunotherapy alone improves efficacy for patients with MPM.
Primary Objectives:
The primary objective is to test whether the combination of platinum-based chemotherapy and pemetrexed with durvalumab / tremelimumab or durvalumab / tremelimumab alone improves recurrence-free survival for patients with resectable MPM compared to historical, published data for surgery with chemotherapy.
Secondary Obje... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/22/2024
Locations: Duke Cancer Institute, Durham, North Carolina +1 locations
Conditions: Mesothelioma
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
Recruiting
The purpose of this study is to evaluate the safety and clinical activity of maintenance olaparib and pembrolizumab following multi-agent, low dose chemotherapy with gemcitabine, nab-paclitaxel, capecitabine, cisplatin, and irinotecan (GAX-CI) in patients with untreated metastatic pancreatic ductal cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/22/2024
Locations: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Metastatic Pancreatic Cancer
409 - 420 of 1422